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Abstract
ING-1(heMAb), a human-engineered monoclonal anti-
body (MAb) that specifically targets the epithelial cell
adhesion molecule (Ep-CAM), kills adenocarcinoma
cells in vitro and inhibits tumor growth in vivo.
In the current study, we evaluated the efficacy of
ING-1(heMAb) in a murine model of cancer metasta-
ses. Mice received intravenous dosing of 1 mg/kg
ING-1(heMAb), twice a week, starting on day 2 or day 5.
A negative control group received 1 mg/kg human im-
munoglobulin G with the same dose frequency starting
on day 2. A positive control group received weekly
100 mg/kg 5-flurouracil/leucovorin starting on day 2.
ING-1(heMAb)/day 2 treatment significantly reduced
both the number of visible tumor nodules in body
cavities (P < .01) and the number of metastases on
lung surfaces (P < .005). The treatment also resulted
in a 91% reduction of micrometastases in lung tissues
(P < .0001). Delaying ING-1(heMAb) treatment until day
5 caused 54% reduction in micrometastases (P < .005).
Our results indicate that a number of parameters, in-
cluding treatment starting day, dose level, and dose
frequency, are critical in achieving the optimal efficacy
of ING-1(heMAb). We conclude that ING-1(heMAb) ef-
fectively reduced tumor metastases in a murine cancer
model. Immunotherapy with ING-1(heMAb) may be
beneficial in treating human metastatic diseases.
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Introduction
Epithelial cell adhesion molecule (Ep-CAM) is a 40-kDa
glycoprotein, which is overexpressed on the membranes of
most adenocarcinoma cells, some squamous cell carcino-
mas, and renal cell carcinoma cells [1–3]. Ep-CAM functions
as a homophilic adhesion molecule that promotes weak,
flexible, intercellular interactions and is thought to play a
physiological role in morphogenesis and embryonic devel-
opment [4]. Although the exact function of Ep-CAM during
tumorigenesis, tumor invasion, and metastasis is still un-
known, increased expression of Ep-CAM is associated with
active proliferation of epithelial cells and has been reported
to correlate with malignant progression of tumors [5,6].
Overexpression of Ep-CAM is detected in a wide variety of
adenocarcinomas, including the colorectum, prostate, pancre-
as, lungs, and breasts [1]. Clinically, Ep-CAM has long been
recognized as a valid tumor target for monoclonal antibody
(MAb)–based cancer immunotherapy. For example, a murine
anti–Ep-CAMantibody called edrecolomabwas among the first
MAbs to enter clinical trials for treatment of Duke’s stageCcolon
cancer [7]. Overall, previous studies have demonstrated that
Ep-CAM is a validated target for passive immunotherapy.
MAbs that recognize tumor-associated antigens are in-
creasingly used for treatment of cancer and metastasis. The
therapeutic MAb used in the present study, ING-1(heMAb), is a
human-engineered immunoglobulin G (IgG)-1 MAb that binds
the Ep-CAM antigen with high affinity [8]. Human engineering
technology uses a unique residue-by-residue analysis to con-
vert a nonhuman antibody variable region to human and
permits direct construction of a fully active human chimeric
antibody [8]. As a result of the human engineering process,
ING-1(heMAb) has minimal immunogenicity in humans [9] and
still retains the antigen-binding specificity of its murine coun-
terpart, Br-1 [10,11]. Br-1 is a mouse antitumor antibody that
was originally generated against breast carcinoma tissues [12].
In addition, ING-1(heMAb) has a half-life of 10 to 20 days in
animal studies, comparable to that of a native IgG [13]. In
addition, ING-1(heMAb) half-life in humans was between 16
and to 35 hours, as determined in a Phase I dose-escalating
study [9]. These properties make ING-1(heMAb) an excellent
candidate for clinical development as a cancer therapeutic.
We have previously demonstrated that ING-1(heMAb) can
promote killing of human tumor cells in the presence of immune
effector cells [13]. The main mechanism underlying the anti-
tumor effect of ING-1(heMAb) has been suggested as anti-
body-dependent cell-mediated cytotoxicity (ADCC) [14]. In
addition, ING-1(heMAb) significantly inhibited the establish-
ment of tumor xenografts [13]. However, MAbs targeting Ep-
CAM in general lack the efficacy to eradicate large tumor
masses. We therefore postulated that ING-1(heMAb) would
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be most effective when used to eliminate metastases and
residual tumor cells. In the current study, we examined the
efficacy of ING-1(heMAb) in treating tumor metastases in a
murine cancer model. In this model, human colon cancer
cells (HT-29) were injected intravenously into nude mice,
resulting in establishment of visible tumor nodules in body
cavities and formation of metastases on lung surfaces and
micrometastases within lung tissues. ING-1(heMAb) treat-
ment was found to be effective in inhibiting the growth of
small tumor nodules, metastases, and micrometastases.
The efficacy of ING-1(heMAb) was especially pronounced
against formation of micrometastases. In most types of solid
cancers, the disseminated metastatic disease, rather than
the primary lesion, is the cause of death of the majority of
patients. Therefore, we believe the potential application of
ING-1(heMAb) in treating cancer metastases offers promise
for therapeutic outcome for cancer patients.
Materials and Methods
Cell Line and Mice
The human colon adenocarcinoma cell line, HT-29, was
purchased from the American Type Culture Collection (Man-
assas, VA). Cells were maintained as monolayers in Eagle’s
defined minimal essential medium (DMEM) supplemented
with 10% fetal bovine serum, sodium pyruvate, and nones-
sential amino acids, and incubated at 37jC with 5% CO2.
Female NCr nu/nu mice (Simonsen Laboratory, Gilroy,
CA), aged 6 to 7 weeks and weighing 20 to 22 grams, were
used. All animals were maintained in a sterile environment.
Cages, bedding, food, and water were all autoclaved, and
animals were handled in a laminar flow hood. They were
housed in an animal facility approved by the American
Association for Accreditation of Laboratory Animal Care.
The animal room was maintained on daily 12-hour light/12-
hour dark cycle. All animal studies were conducted under the
guidelines of the Institutional Animal Care and Use Commit-
tee (IACUC). All animal study protocols have been approved
by the IACUC.
Reagents and Drugs
ING-1(heMAb) was manufactured at XOMA (US) LLC
(Berkeley, CA). Human IgG (in lyophilized form), 5-flurouracil
(5-FU), leucovorin (LV), and Bouin’s solution were pur-
chased from Sigma (St. Louis, MO). ING-1(heMAb) was
supplied as 5 mg/ml in a formulation buffer (20 mM sodium
phosphate, 0.15 M sodium chloride, 0.005% polysorbate
80, pH 7.2). Prior to study initiation, human IgG was recon-
stituted to appropriate concentrations in the ING-1(heMAb)
formulation buffer, and 5-FU and LV were diluted in phos-
phate-buffered saline (PBS) solution. All reagents and drugs
were kept at 2jC to 8jC during the study period.
Experimental Metastasis Model in IL-1–Pretreated Athy-
mic Nude Mice
Female athymic mice were injected through the lateral tail
vein with PBS containing 0.5 mg of recombinant human IL-1b
(purity 97%, ED50 5–10 pg/ml in D10 assay; R&D Systems,
Minneapolis, MN) in order to increase the efficiency of tumor
metastasis in lung tissues [15,16]. Two to 3 hours later,
single-cell suspensions of HT-29 cells (1.5  107 cells/ml in
DMEM) were injected through the intravenous route (0.2 ml
per mouse). On day 2, mice were randomly divided into
various groups (10 per group). Mice received ING-1(heMAb)
once or twice weekly, intravenously, for 3 weeks starting
on either day 2 or day 5. A negative control group received
1 mg/kg human IgG twice weekly for 3 weeks, starting on day
2. In the positive control group, 100 mg/kg 5-FU/LV was
injected intraperitoneally once weekly for 4 weeks, starting
on day 2. At the end of the study (8 weeks), all mice were
sacrificed and subjected to necropsy and tissue collection.
Visible tumor nodules (> 3 mm in diameter) throughout
animal body cavities were examined and counted during
necropsy. Lung tissues were dissected and fixed in a neutral-
buffered formalin/Bouin’s fixative solution (4:1 vol/vol) for 18
to 24 hours followed by changing into 70% ethanol. The
number of tumor nodules on lung surfaces was counted
under a dissecting microscope.
Histology
Lung tissue samples were sent to IDEXX Laboratories
(West Sacramento, CA) for histological analysis. Trimmed
tissues were processed by dehydration, paraffin embedding,
and sectioning. From each lung tissue, five step sections
(7 mm thick each), separated by ~250 mm, were stained with
hematoxylin and eosin. Sections were examined by a pa-
thologist and the number of micrometastasis foci was
counted.
Statistical Analysis
The ANOVA post hoc Bonferroni/Dunn test was used to
compare the results on visible tumor nodules, tumor metas-
tases, and micrometastases. The analyses were performed
between the IgG group and various study groups. A P value
< .05 was considered to be statistically significant. Unless
otherwise noted, all data are presented as mean ± SE.
Results
ING-1(heMAb) Eliminated Visible Tumor Nodules in Body
Cavities of Some Animals
At the end of the study, all animals were humanely
sacrificed and necropsy was performed. To determine
whether ING-1(heMAb) was effective in reducing the size
of large, well-established metastases, visible tumor nodules
(diameter z 3 mm) inside the cavities of animal bodies were
examined and counted. Due to difficulties in counting some
individual nodules, values for each animal were determined
based on a scoring system, as defined in Table 1. As shown
in Table 1A, 90% of animals in the IgG group developed
tumor nodules, with 50% of them scoring more than 20
nodules. ING-1(heMAb), 1 mg/kg, starting on day 2 resulted
in significant reduction of visible tumor nodules in the body
cavities; 70% of the mice were tumor-free at the study
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termination (at 8 weeks, P < .01, versus IgG group).
5-FU/LV, 100 mg/kg, starting on day 2 prevented 50% of
animals from developing visible tumors (P < .01, versus IgG
group). ING-1(heMAb) treatment, starting on day 5, did not
significantly reduce the incidence or the number of tumor
nodules. In a second study, similar results were obtained
with ING-1(heMAb) at 1 mg/kg (data not shown). Further-
more, as shown in Table 1B, ING-1(heMAb), starting on day
2, remained effective at 0.3 mg/kg, preventing 50% of the
mice from developing visible tumors (P < .01, versus IgG
group). However, the efficacy of ING-1(heMAb) at 0.3 mg/kg
was diminished when the dose frequency was reduced from
twice a week to once a week (Table 1B).
Reduction of Tumor Metastases on Lung Surfaces in Mice
Treated with ING-1(heMAb)
After necropsy, organs including the lungs, liver, spleen,
and kidneys were collected and fixed in diluted Bouin’s
solution. To evaluate the efficacy of ING-1(heMAb) against
metastases on organ surfaces, tissues were examined and
metastases were counted under a dissecting microscope.
No metastases were detected on the liver, spleen, or
kidneys in any group (data not shown). In contrast, a
significant number of metastases were observed on lung
surfaces in the IgG control group (Figure 1). As shown in
Figure 1A, 1 mg/kg ING-1(heMAb)/day 2 treatment
resulted in 86% reduction of the average number of
metastases when compared with the IgG group (from
12.1 to 1.7) (P < .005, versus IgG group). However, when
ING-1(heMAb) treatment was delayed until day 5, no
significant reduction of metastasis nodules was observed
(Figure 1A). 5-FU/LV, 100 mg/kg, starting on day 2 also
resulted in 79% of metastases reduction (from 12.1 to 2.5)
(P < .005, versus IgG group). In a second study, similar
results were obtained with ING-1(heMAb) at 1 mg/kg (data
not shown). As shown in Figure 1B, ING-1(heMAb)/day
2 treatment at 0.3 mg/kg still inhibited tumor metastases by
89% (from 21.3 to 2.3) (P < .005, versus IgG group). When
the dose frequency was reduced to once weekly, 0.3 mg/kg
ING-1(heMAb) inhibited metastases by 46%; however, the
inhibition failed to reach statistical significance (Figure 1B).
Inhibition of Micrometastases Formation in Lung Tissues by
ING-1(heMAb)
After being examined under a dissecting microscope,
lung tissues from all animals were processed into slides
and stained with hematoxylin and eosin for cell morphology.
The slides were examined by a pathologist in a blind fashion
to determine the total number of micrometastasis foci from
each lung section. Examination of lung sections for animals
treated with ING-1(heMAb) demonstrated that micrometas-
tases were reduced in all three treatment groups compared
to the IgG group. As shown in Figure 2A, compared with the
IgG group, 1 mg/kg ING-1(heMAb)/day 2 treatment reduced
the average number of micrometastasis foci by 91%
(from 17.3 to 1.6) (P < .0001, versus IgG group). 5-FU/LV,
100 mg/kg, resulted in a 76% decrease of the number of foci
(from 17.3 to 4.1) (P < .0001, versus IgG group). ING-
1(heMAb) treatment starting on day 5 also resulted in an
inhibitory effect against micrometastases, reducing the foci
number by 54% (17.3 to 8.0) (P < .005, versus IgG group). In
a second study, similar results were observed with ING-
1(heMAb) at 1 mg/kg (data not shown). In contrast to the
results obtained on visible tumor nodules and tumor metas-
tases, ING-1(heMAb)/day 2 treatment at 0.3 mg/kg, either
twice a week or once a week, was effective in inhibiting
micrometastases. As shown in Figure 2B, twice weekly
dosing led to 84% reduction of micrometastases (P < .0001,
versus IgG group), whereas once weekly dosing resulted in
a 73% reduction (P < .0001, versus IgG group).
Discussion
The dissemination of cancer metastases remains the princi-
pal cause of death in cancer patients. Despite the lethal
nature of cancer, to date, no effective treatment is available
to counter its progression, and prognosis for patients with
metastatic diseases remains very poor [17]. Innovative ther-
apeutic strategies are needed in order to effectively treat
metastases and to prolong patients’ lives. Therapeutic
MAbs, either alone or conjugated with cytotoxic agents, have
Table 1. Visible Tumor Nodules During Necropsy.
A
Animal* IgG ING-1/d2y ING-1/d5 5-FU/LVy
1 mg/kg 1 mg/kg 1 mg/kg 100 mg/kg
1 +++ ++ +++ +++
2 +++ ++ +++ ++
3 +++ + +++ ++
4 +++ 0 +++ +
5 +++ 0 +++ +
6 ++ 0 ++ 0
7 ++ 0 ++ 0
8 + 0 ++ 0
9 + 0 + 0
10 0 0 0 0
B
Animal IgG ING-1/2  wy ING-1/1  w
1 mg/kg 0.3 mg/kg 0.3 mg/kg
1 +++ + +++
2 +++ + ++
3 +++ + ++
4 ++ + ++
5 ++ + ++
6 ++ 0 ++
7 ++ 0 +
8 ++ 0 +
9 ++ 0 +
10 + 0 +
In each study group, animals were listed based on the order of the number of
visible tumor nodules, from the highest to the lowest. In both panels, 0: no
tumor; (+) 1 to 10 tumor nodules; (++) 11 to 20 tumor nodules; (+++) > 20
tumor nodules. IgG: IgG starting on day 2. In panel (A), ING-1/d2:
ING-1(heMAb) starting on day 2; ING-1/d5: starting on day 5; 5-FU/LV: 5-
FU/LV starting on day 2. In panel (B), ING-1/2  w: ING-1(heMAb)/day 2,
twice weekly; ING-1/1  w: ING-(heMAb)/day 2, once weekly.
*Mice received 3  106 HT-29 cells intravenously on study day 1.
yP < .01, versus IgG group.
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shown promise in inhibiting tumor invasion and metastasis
[18]. Here we have investigated the use of the human-
engineered MAb, ING-1(heMAb), as a means of specifically
targeting immune effector cells to Ep-CAM expressing tumor
metastases in vivo.
Previous studies onMAbs targeting human Ep-CAM have
demonstrated significant antitumor activities, both in vitro
and in vivo [19,20]. The mechanism by which anti–Ep-CAM
antibodies, including ING-1(heMAb), exert their therapeutic
efficacy appears to be the activation of ADCC through
Figure 1. ING-1(heMAb) treatment on day 2 reduces number of tumor metastases on lung surfaces. Upon necropsy, lung tissues from all mice were dissected and
fixed in diluted Bouin’s solution. Each lung sample was examined under a dissecting microscope and tumor metastases were identified and counted. The column
represents the average number of tumor metastases based on 10 mice per group. The error bar is standard error. In both panels, IgG: IgG starting on day 2. In
panel (A), ING-1/d2: ING-1(heMAb) starting on day 2; ING-1/d5: ING-1(heMAb) starting on day 5; 5-FU/LV: 5-FU/LV starting on day 2. In panel (B): ING-1/2W:
ING-1(heMAb) at 0.3 mg/kg treated twice weekly; ING-1/1W: ING-1(heMAb) at 0.3 mg/kg treated once weekly. **P < .005 (ANOVA post hoc Bonferroni/Dunn test).
Figure 2. ING-1(heMAb) treatment at all dose schedules significantly inhibited tumor micrometastases in lung tissues. The lung tissues were sent to IDEXX
Laboratories for slide processing and hematoxylin and eosin staining. The column represents the average number of micrometastases per slide and the error bar is
the standard error. In both panels, IgG: IgG starting on day 2. In panel (A), ING-1/d2: ING-1(heMAb) starting on day 2; ING-1/d5: ING-1(heMAb) starting on day 5;
5-FU/LV: 5-FU/LV starting on day 2. In panel (B): ING-1/2W: ING-1(heMAb) at 0.3 mg/kg treated twice weekly; ING-1/1W: ING-1(heMAb) at 0.3 mg/kg treated
once weekly. **P < .005, ***P < .0001 (ANOVA post hoc Bonferroni/Dunn test).
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interaction with host immune effector cells. We have used
nude mice in all previous and present in vivo studies.
Although lacking functional T-cell–mediated immunity, these
mice retain the effector cells required for mounting ADCC
responses; those cells include macrophages, natural kil-
ler cells, and neutrophils. We have previously reported that
ING-1(heMAb) can significantly suppress the growth of
human colon tumor HT-29 and prostate tumor PC-3 in
murine xenograft models [13]. The degree of growth sup-
pression is dose-dependent, with 1 mg/kg providing the
greatest benefit.
Although it is highly effective in preventing and/or inhibit-
ing tumor establishment in xenograft models, other preclin-
ical studies evaluating the in vivo efficacy of ING-1(heMAb)
have not yet demonstrated its ability to eradicate large, well-
established, solid tumors in xenograft models (Ruan et al.,
unpublished data). Similar findings were associated with
other anti–Ep-CAM antibodies [20]. A number of factors—
including antibody localization into the tumor, tumor vascu-
larization, and immune effector cells—that may limit the
effectiveness of some MAbs have been identified [21,22].
ING-1(heMAb) may be particularly useful as an adjuvant
therapy after resection of primary tumors to prevent tumor
recurrence and to eliminate tumor metastases. In this study,
we investigated the efficacy of ING-1(heMAb) in a cancer
metastasis model, in which metastases were formed by
injecting tumor cells directly into the blood vessels. We
selected this model over the traditional flank tumor model
because this model provides a simple, reproducible ap-
proach to studying metastases. In contrast, traditional flank
models rarely generate the necessary metastasis character-
istics to show the optimal efficacy of ING-1(heMAb). In this
experimental cancer model, the efficacy of ING-1(heMAb)
was clearly demonstrated in inhibiting tumor metastases and
micrometastases.
In this study, we have systematically analyzed metas-
tasis data at visual, microscopic, and cellular levels. Three
different endpoints were chosen for determining
ING-1(heMAb) efficacy: visible tumor nodules, tumor me-
tastases on lung surfaces, and micrometastases in lung
tissues. We found that ING-1(heMAb) at 1 mg/kg, starting
on day 2, was highly effective in inhibiting all three end-
points. First, ING-1(heMAb) significantly reduced and, in
some animals, completely eliminated visible tumor nodules
as determined during necropsy (P < .01, versus IgG
group). Second, a significant reduction of metastases on
lung surfaces was observed in the ING-1(heMAb)/day 2–
treated group (P < .005, versus IgG group). Lastly,
ING-1(heMAb) treatment, starting on day 2, resulted in
91% reduction of micrometastases in lung tissues
(P < .005, versus IgG group). Among the three endpoints,
the whole body nodule data suggest that ING-1(heMAb) is
the most effective against nodules in body cavities be-
cause 50% of animals had no nodules. We postulate that
tumor nodules in body cavities are most accessible for
immune effector cells; therefore, ING-1(heMAb) elicits the
most potent ADCC activity against these nodules. Delaying
ING-1(heMAb) treatment until day 5 resulted in loss of
efficacy on the first two endpoints. However, day 5 treat-
ment still led to 54% reduction in micrometastases
(P < .005, versus IgG group). These results indicate that
treatment started early (day 2) was more effective than
delayed (day 5) treatment. The difference in results
obtained with early and delayed treatment may be due to
a difference in time available for growth of disseminated
tumor cells. Thus, on day 2, tumor cells were still in early
stages of micrometastasis formation; however, by day 5,
metastases likely have started active growth. This expla-
nation is consistent with the previously proposed mecha-
nism of action for ING-1(heMAb), which predicts that the
size of metastasis nodules limits the access of the MAb
and the immune effector cells to the target cells and,
consequently, affects its activity in vivo [20]. These data
suggest that ING-1(heMAb) should be most active in the
adjuvant setting, where the targets are circulating tumor
cells and metastases. This proposed clinical use is consis-
tent with the clinical findings that many MAb treatment
trials in patients with measurable tumor burdens have not
been successful.
Our studies also identified experimental parameters that
contribute to the optimal efficacy of ING-1(heMAb) against
metastases. In addition to the starting day of MAb treatment
as discussed above, we have observed that the dose level
and dose frequency are interdependent in determining
ING-1(heMAb) efficacy. When its dose frequency was twice
weekly, ING-1(heMAb) remained active at 0.3 mg/kg as
determined by the three endpoints. When the dose frequen-
cy was reduced to once weekly, ING-1(heMAb) at 0.3 mg/kg
was less active: activity against visible nodules and metas-
tases was not evident, but activity against micrometastases
was retained. These results indicate that in order to achieve
its full antimetastasis potential, ING-1(heMAb) needs to be
administered at a sufficient dose frequency to maintain its
steady-state level in the blood. From our current study, we
conclude that, at a minimum, twice weekly dosing is required
for ING-1(heMAb) to be effective against metastases in this
model. In addition, among the three endpoints, micrometa-
stases appear to be most susceptible to ING-1(heMAb),
again suggesting that the earlier the stage of metastatic
disease is, the more effective is the ING-1(heMAb) therapy.
In summary, the following conclusions can be derived
from these studies. First, our results support that a MAb
designed to elicit ADCC activity such as ING-1(heMAb) can
be a useful means of inhibiting metastasis. Previous exam-
ples of successful development of MAbs that are dependent,
at least partially, on ADCC activity include herceptin and
rituximab from Genentech, Inc. (South San Francisco, CA)
[23]. Moreover, our studies provided proof-of-principle that
ING-1(heMAb) treatment can lead to significant reduction of
metastases and micrometastases, and this protection is at
least equal to that provided by the standard 5-FU/LV che-
motherapy. Lastly, ING-1(heMAb) treatment was more ef-
fective when it was administered at earlier stages of
metastases development. ING-1(heMAb) was particularly
effective when administered early in the study (on day 2),
whereas day 5 treatment was also effective in reducing
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micrometastases. Taken together, ING-1(heMAb) effectively
reduced tumor metastases in a murine model of human
cancer and these results support the use of ING-1(heMAb)
as a clinical therapy against tumor metastases. We believe
that ING-1(heMAb) may show potential as a targeted therapy
in treating minimal residual diseases or early metastases. In
addition, to obtain further enhancement of antimetastasis
activity, the combined modality using ING-1(heMAb) with
other anticancer treatments should also be considered.
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